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ABSTRACT
Medullary thyroid cancer (MTC) relies on the aberrant activation of RET proto-
oncogene. Though targeted approaches (i.e., tyrosine kinase inhibitors) are available, 
the absence of complete responses and the onset of resistance mechanisms indicate 
the need for novel therapeutic interventions. Due to their role in regulation of 
gene expression, G-quadruplexes (G4) represent attractive targets amenable to 
be recognized or stabilized by small molecules. Here, we report that exposure of 
MTC cells to a tri-substituted naphthalene diimide (NDI) resulted in a significant 
antiproliferative activity paralleled by inhibition of RET expression. Biophysical 
analysis and gene reporter assays showed that impairment of RET expression was 
consequent to the NDI-mediated stabilization of the G4 forming within the gene 
promoter. We also showed for the first time that systemic administration of the NDI 
in mice xenotransplanted with MTC cells resulted in a remarkable inhibition of tumor 
growth in vivo. Overall, our findings indicate that NDI-dependent RET G4 stabilization 
represents a suitable approach to control RET transcription and delineate the rationale 
for the development of G4 stabilizing-based treatments for MTC as well as for other 
tumors in which RET may have functional and therapeutic implications.
INTRODUCTION
Medullary thyroid cancer (MTC) is a malignant 
disease arising from neural crest-derived thyroid 
parafollicular C cells [1, 2]. It may occur both sporadically 
(75 % of cases) and in a context of inherited tumor 
syndromes (25 % of cases), presenting as multiple 
endocrine neoplasia (MEN) type 2A (80 %), MEN2B 
(5 %), or familial MTC (15 %) [1, 2].
The RET (REarranged during Transfection) proto-
oncogene is tightly associated with MTC development 
[3]. RET-activating germline point mutations are the 
driver events in MEN2 syndromes whereas somatic 
mutations of RET proto-oncogene are present in 30-50 % 
of sporadic MTC [1, 2]. RET gene encodes a single-
pass transmembrane tyrosine kinase receptor which is 
expressed in cells deriving from the branchial arches, 
the neural crest and the urogenital system [3, 4]. By 
direct phosphorylation of multiple downstream targets, 
the mutant RET tyrosine kinase receptor controls the 
proliferation and survival of MTC cells [3, 4].
Total thyroidectomy represents the only curative 
option for MTC [5]. Unfortunately, most MTCs are 
diagnosed when the disease is already metastatic and 
often exhibits resistance to chemo- and radio-therapy [1–
5]. Several preclinical studies have provided compelling 
evidence on the relevance of RET as promising therapeutic 
target [5, 6]. Though targeted approaches based on the use 
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of tyrosine kinase inhibitors (TKIs), such as vandetanib 
or cabozantinib, have represented a breakthrough for 
the treatment of metastatic disease [5], the absence of 
complete responses in clinical trials highlights the need 
for treatment optimization. In addition, the occurrence of 
primary and/or secondary resistance mechanisms, such as 
the described point mutation in Valine 804 of RET receptor 
[7], represents a worrisome event for the treatment 
of advanced MTC with selected TKIs. Therefore, the 
development of novel therapeutic interventions for the 
advanced disease is a mandatory issue.
G-quadruplexes (G4s) are peculiar structures that 
can form in guanine-rich nucleic acids [8, 9]. They are 
composed of four guanine residues self-assembled into 
stable planar arrays, known as G-quartets, in which 
guanines are interconnected by Hoogsteen hydrogen bonds 
[8, 9]. The stacking of two or more G-quartets results in 
the formation of a G4 supramolecular structure, which 
may be stabilized by monovalent cations (e.g., Na+; K+) 
and ligands, including small molecules and proteins [8, 
9]. Nucleic acid sequences that may fold into G4 structure 
exhibit a consensus motif (i.e., G4 forming motif), which 
consists of at least four runs of guanines containing 
three or more guanine residues (e.g., [G
≥3
Nx]≥4, where N 
is any nitrogen base and X a number between 1 and 7) 
[9]. Genome-wide analyses have revealed an extensive 
representation of G4 forming motifs throughout the 
human genome [9]. Other than in telomeres, these motifs 
are particularly abundant within the replication origins 
and, at gene level, within the promoter regions flanking 
the transcription start site (TSS), the 5′ untranslated 
region (UTR) and the 5′ end of the first intron [10, 11]. 
Conversely, G4 forming motifs are poorly represented 
at the 3′-UTRs and almost absent in exons [10, 11]. 
Furthermore, oncogene rather than tumor suppressor 
gene promoters are chiefly enriched in these motifs, thus 
suggesting an evolutionary selection for G4 structures 
based on gene function [12].
Although the physiological role of G4s still needs 
to be fully elucidated, a growing body of evidence points 
them out as attractive targets to defeat cancer [13]. In this 
context, G4s exhibit a variety of well-defined structural 
elements such as molecularity, strand and loop orientation 
(generally defined as topology), loop composition/
length and groove features [8–12]. Such a diversity of 
G4 structural elements provides, at least in principle, 
a repertoire of specific druggable sites amenable to be 
efficiently recognized and stabilized by small molecules 
(i.e., G4-ligands or G4 stabilizing agents) for therapeutic 
purposes [13, 14].
This evidence has indeed fuelled the search for 
compounds able to interact with and to target such 
secondary DNA structures [14]. A variety of G4-
stabilizing small molecules identified during the last 
decade are currently considered as fascinating weapons 
to therapeutically operate at genomic level and represent 
an entirely novel, though still challenging, approach to 
anticancer drug design and development [14]. These agents, 
belonging to different chemical families [13], have been 
demonstrated to selectively interact with and efficiently 
favor the folding or the stabilization of G4 structures in a 
variety of target nucleic acid sequences [13].
By analogy to other TATA-less promoters (e.g., 
MYC, KRAS and VEGF genes), the proximal region 
upstream the TSS of RET gene contains two G-rich 
boxes that are essential for basal promoter activity and 
are characterized by a typical G4 forming motif [8, 
15, 16]. On the basis of this evidence, we investigated 
the biological effects of a naphthalene diimide (NDI) 
derivative, previously identified to act as both G4 
ligand [17] and a selective photoreactive warhead 
targeting G4s [18], in two MTC cell lines. Results 
showed that the exposure of MTC cells to the NDI 
derivative resulted in a marked impairment of in vitro 
tumor cell growth, which was tightly associated with 
a remarkable down-regulation of RET, both at mRNA 
and protein levels. Such an effect was due to the 
capability of the compound to stabilize the G4 structure 
that spontaneously forms within a region proximal 
to the TSS of the oncogene promoter, as revealed by 
biophysical and gene reporter assays. Moreover, we also 
provided evidence that in vivo systemic administration 
of the NDI derivative resulted in growth inhibition of 
tumors originated from MTC cells xenotransplanted 
into immunocompromised mice.
Overall, our findings suggest that RET G4 
stabilization by small molecules may represent a suitable 
tool to control oncogene transcription for therapeutic 
purposes in RET-dependent MTC, and furnish the 
biological rationale for the development of novel G4 
stabilizing-based treatment approaches that could be 
extended to other oncogene-driven neoplastic diseases.
RESULTS
Evaluation of the biological effects of the NDI 
derivative in MTC cells
The biological effects of the NDI derivative (Figure 1A) 
were investigated in two human MTC cell lines, namely TT 
cells harboring both a MEN2A-type C634W RET mutation 
and a tandem duplication of the mutated RET allele [19] 
and MZ CRC-1 cells harboring the M918T RET mutation 
found in about 50 % of sporadic MTC and the most common 
RET mutation in the MEN2B syndrome, associated with an 
aggressive disease behavior [19].
The capability of the NDI to inhibit the in vitro 
growth of MTC cells was investigated. A 48-h exposure 
of both MTC cell lines to increasing concentrations of the 
NDI resulted in a remarkable and concentration-dependent 
inhibition of cell growth (Figure 1B), with IC50 values in 
the low micromolar range (1.8 ± 0.3 and 1.7 ± 0.2 μM for 
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Figure 1: Exposure of MTC cells to the NDI derivative resulted in the impairment of cell growth and in a remarkable 
down-regulation of RET expression. A. Chemical structure of the NDI derivative [17]; B. Cell growth inhibition curves obtained upon 
a 48-h exposure of MZ CRC-1 (●) and TT cells (○) to increasing concentrations (Log10[μM]) of NDI. Data have been reported as percentage 
of growing cells in treated vs. untreated cells and represent mean values ± s.d.; C. Real-time RT-PCR assessment of RET mRNA expression 
in MZ CRC-1 (white columns) and TT (black columns) cells exposed for 24 h to increasing concentrations of NDI. Quantification of RET 
mRNA levels was carried out according to the 2-ΔΔCt method. Data have been reported as RET mRNA relative quantity in treated vs. untreated 
cells and represent mean values ± s.d.; D. Representative western immunoblotting showing basal and phosphorylated (pRET/Y1062) RET 
protein amounts in MTC cells exposed for 24 h to the indicated concentrations of NDI. β-actin (ACTB) was used to ensure equal protein 
loading; E. Time-course assessment of RET mRNA expression levels in untreated MZ CRC-1 (●) and TT (■) cells and after the exposure 
to an equitoxic amount of NDI (MZ CRC-1 (○) and TT (□)). Data have been reported as RET mRNA relative amounts in untreated and 
NDI-treated cells, according to 2-ΔC’T method [39], and represent mean values ± s.d.; F. Representative western immunoblotting showing the 
time-course assessment of basal and phosphorylated (pRET/Y1062) RET protein amounts in untreated and NDI-treated MZ CRC-1 (upper 
panel) and TT (lower panel) cells; G. Time-course evaluation of cell growth in untreated (●) and NDI-treated (○) MZ CRC-1 (left panel) 
and TT (right panel) cells. Data have been reported as number of growing cells and represent mean values ± s.d..
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MZ CRC-1 and TT cells, respectively). The NDI-mediated 
inhibition of MTC cell growth was associated with a marked 
down-regulation of RET expression. In particular, real-time 
RT-PCR analyses showed a nearly complete abrogation of 
RET mRNA levels in cells exposed for 48 h to 1 μM (0.24 
± 0.03 and 0.20 ± 0.01 relative quantity with respect to 
untreated cells in MZ CRC-1 and TT cells, respectively) 
and 2 μM (0.14 ± 0.02 and 0.08 ± 0.006 relative quantity 
with respect to untreated cells in MZ CRC-1 and TT cells, 
respectively) of the compound (Figure 1C). The reduction 
of RET mRNA expression levels was paralleled by the 
depletion of either the basal and phosphorylated forms of 
RET protein in both cell lines exposed to the NDI derivative 
(Figure 1D). Furthermore, the NDI-mediated inhibition of 
RET transcription and reduction of protein amounts was 
consistently observed up to 96 h in both cell lines treated 
with an equitoxic concentration (IC50s) of the compound 
(Figure 1E and 1F). Such an effect was paralleled by a 
pronounced impairment of MTC cell growth over time. 
In particular, while untreated cells showed an exponential 
growth (according to their respective doubling times) 
during the time course of the experiments (Figure 1G), the 
number of NDI-treated cells was progressively reduced 
(MZ CRC-1 cells) or remained constant (TT cells) at the 
different time points (Figure 1G).
To further explore the therapeutic potential of the 
NDI, we assessed its cytotoxic activity in an in vitro model 
of estrogen-receptor positive breast cancer (BCa), a tumor 
type for which anti-RET therapy may represent a novel 
treatment option [20]. Specifically, a 48-h exposure of 
wild-type RET expressing MCF-7 cells [20] to increasing 
concentrations of NDI resulted in a dose-dependent 
inhibition of cell growth (Supplementary Figure S1A), with 
an IC50 value (1.35 ± 0.05 μM) comparable to that obtained 
in MTC cells. The NDI-mediated impairment of MCF-7 
cell growth was paralleled by a concentration-dependent 
decrease of RET mRNA and protein levels (Supplementary 
Figure S1B and S1C). In addition, the exposure of MCF-7 
cells to a concentration of NDI corresponding to the IC50 
triggered a persistent inhibition of RET transcription over 
the time course of the experiment (Supplementary Figure 
S1D), although a noticeable decrease in RET mRNA 
levels and protein amounts over time was also observed 
in untreated, exponentially growing cells (Supplementary 
Figure S1D, S1E and S1F). Nevertheless, a remarkable and 
time-dependent arrest of cell growth (Supplementary Figure 
S1F) was appreciable in NDI-treated compared to untreated 
MCF-7 cells (Supplementary Figure S1F).
To verify whether the NDI-mediated modulation of 
endogenous RET protein levels was determinant for the 
antiproliferative activity of the compounds, RET protein/
oncoprotein expression was partially restored by transient 
transfection of plasmids encoding the MEN2A-associated 
C634R RET (pRc-protoRETC634R) variant and the wild-
type RET (pRc-protoRETWT), respectively, in TT and 
MCF-7 cells.
Of note, after a 48-h exposure to NDI (IC50) a slight, 
though significant, rescue of cell growth was appreciable in 
RET- compared to empty vector (mock control)-transfected 
cells (69 ± 5.5 % vs. 54.8 ± 2.0 % and 73.4 ± 10 % vs. 54.4 ± 
7.5 % for TT and MCF-7 cells, respectively; Supplementary 
Figure S2A). Furthermore, such a rescue in cell growth was 
consistently observed up to 96 h in RETWT-transfected MCF-
7 cells, which showed significantly higher amounts of RET 
protein, before and after NDI treatment, compared to mock 
control (Supplementary Figure S2B). This evidence indicates 
that the ectopic reconstitution of RET may counteract the 
cell growth inhibitory activity of NDI, thus suggesting that 
the antiproliferative activity of the compound may be partly 
limited by the amounts of RET protein.
We have found that NDI exerted a cytotoxic and a 
cytostatic effect in MZ CRC-1 and TT cells, respectively 
(Figure 1F). This evidence was further confirmed by 
the observation that the exposure of MZ CRC-1 cells 
to the NDI derivative resulted in induction of apoptosis 
(Figure 2). Specifically, the TUNEL assay revealed a 
significant increase in the percentage of apoptotic cells 
upon exposure to the compound for 48 h [19.8 ± 1.0 % 
(IC50) and 25.5 ± 1.5 % (IC80); P<0.05] and 72 h [17.5 ± 
1.5 % (IC50) and 23.0 ± 2.0 % (IC80); P<0.01] compared 
to untreated cells, in which the apoptotic rate was <10% 
at both time points considered (Figure 2A). In addition, 
biochemical analyses revealed a noticeable accumulation 
of p53 and a remarkable increase in the cleavage of 
caspase-9 and caspase-3 after a 48- and 72-h exposure to 
the NDI derivative (Figure 2B). Moreover, a prominent 
boost of γ-H2AX was appreciable at 72 h in NDI-treated 
compared to untreated MZ CRC-1 cells (Figure 2B), which 
is in keeping with the kinetic of apoptotic-induced DNA 
fragmentation. By contrast, no evidence of apoptosis, in 
terms of both positivity to TUNEL assay and activation of 
apoptotic effectors, was observed in TT cells upon exposure 
the NDI at both time points (Figure 2C and 2D). However, 
an increase in the levels of γ-H2AX which was associated 
with a remarkable accumulation of p21waf1, a cyclin-
dependent kinase inhibitor which mediates p53-dependent 
cell cycle arrest in response to a variety of stress stimuli, was 
observed after a 48- and 72-h exposure of TT cells to NDI. 
In addition, the accumulation of p27Kip1, which is known 
to cooperate with p21waf1 in the activation of stress-induced 
cell senescence [21], was also appreciable in TT cells after a 
48-h treatment with NDI (Figure 2D). Similarly, a cytostatic 
activity associated with a marked accumulation of p21waf1 
(Supplementary Figure S1E and S1F) was also observed 
in MCF-7 cells upon a prolonged exposure to NDI. On 
the contrary, no changes in p21waf1 and p27Kip1 levels were 
observed in NDI-treated compared to untreated MZ CRC-1 
cells at both time points (Figure 2D). This evidence would 
indicate that treatment with the NDI triggers an apoptotic 
cell response in MZ CRC-1 cells, whereas it likely results in 
a senescent phenotype in apoptosis-deficient TT and MFC-7 
cells [22–24].
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The NDI derivative efficiently recognizes 
and stabilizes the G4 structure within 
RET promoter
On the basis of the evidence that RET promoter 
contains a typical G4 forming motif (Figure 3A) and on 
the observed NDI-mediated decrease of RET levels in 
cancer cells (Figure 1 and Supplementary Figure S1), 
we investigated by biophysical assays whether the NDI 
derivative was able to favor the formation and/or the 
stabilization of G4 structures within the RET promoter. 
Three different RET model oligonucleotides were assayed 
by circular dichroism (CD): the full-length (FL) sequence 
comprising five G-tracts (G-tracts I-V), and two truncated 
sequences corresponding to G-tracts I-IV and II-V, which 
contain the minimum number of G-tracts required to form 
a G4 (Figure 3A and Supplementary Table S1). G-tracts 
I-IV have been reported to form the major G4 structure 
within the FL RET sequence [15]. In the presence of 
physiological concentration of K+, CD spectra of the 
tested RET sequences were all distinctive of G4 topologies 
(Figure 3B). In particular, RET FL and RET I-IV 
sequences formed a parallel-type G4 structure showing 
a major positive peak at 263 nm and a negative peak at 
242 nm, in accordance with previously reported data 
showing that G-tracts I-IV formed a parallel G4 structure 
[15, 16]. RET II-V formed a hybrid-type G4 structure with 
two positive peaks at around 260 nm and 290 nm and a 
negative peak at around 240 nm. The stability of these G4s 
was dependent on the presence of K+ (Table 1).
Upon addition of the NDI, CD analysis showed no 
major conformational variation for RET FL and RET I-IV, 
while RET II-V inverted the intensity of peaks at 265 and 
290 nm (Figure 3C); however, all RET G4s displayed a 
remarkable increase in their stability (Tm>95 °C, Table 
1  and Figure 3B and 3C) with significant variation of 
the Tm recorded in the presence vs. the absence of the 
compound at all tested K+ concentrations (Table 1). To 
allow assessment of the best stabilized sequence, NDI/
DNA ratio was next set to 1 to avoid reaching Tm values 
above 95°C, which would hinder comparison. In these 
conditions, RET II-V was stabilized by the NDI to a higher 
extent compared to RET FL and RET I-IV (5.6°C vs 1.2-
1.3°C, Supplementary Table S2). Such a stabilization was 
Figure 2: Exposure of MTC cells to NDI resulted in either a cytotoxic or cytostatic effect. A. and C. Quantification of apoptosis 
induction in MZ CRC-1 (A) and TT (C) cells upon a 48- and 72-h exposure to NDI (IC50s and IC80s). Data have been reported as percentage 
of TUNEL (apoptotic)-positive cells within the overall cell population and represent mean values ± s.d. *P<0.05; **P<0.01; B. and D. 
Representative western immunoblottings showing the amounts of apoptosis- and cell cycle-related factors in MZ-CRC1 (B) and TT (D) cells 
upon a 48- and 72-h exposure to an equitoxic amount (IC50s) of NDI. Numbers on the left of each panel indicate the molecular weights (kDa) 
used as reference for the correct identification of caspase-9 and -3 cleavage products. β-actin (ACTB) was used to ensure equal protein loading.
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partly selective for RET, since the G4s formed by c-Kit1 
and c-Myc oncogene promoters were stabilized to a lesser 
extent than RET II-V (1.5 and 3.6 °C; Table S2).
To confirm the ability of the NDI derivative to 
stabilize the RET G4 conformation in extended DNA 
sequences, a Taq polymerase stop assay was performed 
using RET FL and RET I-IV templates (Supplementary 
Table S1). Specifically, in the presence of K+, minor 
stop sites corresponding to bases right before Gs at the 
most 3′-end of the G-tracts were visible in both RET 
templates, but not in a control unable to fold into G4 (see 
* in Figure 3D, lanes 2). Upon addition of increasing 
amounts (0.008-1 μM) of the NDI, the intensity of the 
stop bands greatly increased (Figure 3D, lanes 3-6), 
indicating an effective stabilization of the G4 structures 
by the compound even in an extended DNA template. 
Remarkably, a high stabilization of the structure was 
achieved at nM concentrations of the compound (Figure 
3D, lanes 3-5), whereas only at 1 μM, the highest NDI 
tested concentration (Figure 3D, lanes 6), Taq polymerase 
activity was inhibited non-specifically, as revealed by the 
occurrence of a faint stop site also on the control template 
(Figure 3D, lanes 6).
Next, two point mutations (G>A and G>T), 
the position of which was selected on the basis of the 
evidence that G residues 3, 8, 13 and 18 within guanine 
runs II and IV are involved in the formation of G-tetrads 
[15], were inserted (Figure 3A) and their effect on G4 
formation was tested in three templates (RET FL Mut, 
RET I-IV Mut and RET II-V Mut, Supplementary Table 
S1). Spectroscopic analyses showed that, even in the 
presence of K+ 100 mM, the RET I-IV Mut and RET 
II-V Mut oligonucleotides essentially failed to fold into 
a canonical G4 conformation and that the RET FL Mut 
sequence was highly impaired in its folding because, 
while still showing a G4-like CD signature, the molar 
ellipticity was dramatically decreased (Figure 4A). In 
the presence of the NDI, the shoulder at 290 nm slightly 
increased in the RET FL Mut sequence, whereas no 
G4 signatures were yet appreciable in the RET I-IV 
Mut and RET II-V Mut oligonucleotides (Figure 4B). 
However, the RET FL Mut sequence was only mildly 
Figure 3: Biophysical analysis of the RET proto-oncogene promoter G-rich sequence. A. Schematic representation of the 
wild-type G-rich sequence located within the proximal region of RET proto-oncogene promoter. Dashed squares delimitate the two GC 
boxes, according to Guo K. et al. [15]. The five G-tracts are labelled by roman numbers. The RET mutated sequence is also shown. Points 
mutations (G>A and G>T) within G-tract II and IV are highlighted in bold; B. Representative CD spectra of the RET FL as well as of RET 
I-IV and RET II-V truncated oligonucleotides (4 μM) recorded in the presence of 25 mM K+. (Continued )
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stabilized by the compound (Tm 67°C), especially in 
light of the significant stabilization imparted to the wild-
type sequence (Tm > 95 °C) (Supplementary Figure S3). 
These data were further confirmed by a Taq polymerase 
stop assay. No major products of Taq polymerase arrest 
were observed in all tested sequences in the presence of 
the NDI, except for a minor stop site appreciable within 
the RET FL Mut template (Figure 4C). Nonetheless, 
such a stop site did not prevent the Taq polymerase to 
fully synthesize the whole sequence (Figure 4C, RET 
FL MUT, lane 3), conversely to what observed with the 
wild-type RET FL template under the same experimental 
conditions (Figure 3D). These data indicate that point 
mutations inhibited to a great extent, though not 
completely, the capability of the full-length G-rich region 
of the RET promoter to fold in a G4 structure.
Figure 3: (Continued ) Biophysical analysis of the RET proto-oncogene promoter G-rich sequence. C. Representative CD 
spectra of 4 μM RET oligonucleotides (see panel B) recorded in the presence of 25 mM K+ and 16 μM NDI. D. Image of a typical Taq 
polymerase stop assay. The RET FL and RET I-IV templates were amplified by the Taq polymerase in the absence (lanes 1) and presence 
of 10 mM K+, alone (lane 2) or combined with increasing amounts (0.008, 0.04, 0.2 and 1 μM) of NDI (lanes 3-6). A template (non-G4 cnt) 
made of a scramble sequence unable to fold into G4 was also used as internal control. Lane M: ladder of markers obtained by the Maxam 
and Gilbert sequencing carried out on the amplified strand complementary to the template strand. Lane P: unreacted labelled primer. The 
base sequence of the RET FL template corresponding to the stop sites is shown on the left of the gel image. G bases are shown in bold. 
Asterisks indicate G4-specific Taq polymerase stop sites.
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Figure 4: Biophysical analysis of the mutated RET promoter sequence. A. Representative CD spectra of the RET FL Mut, RET 
I-IV Mut and RET II-V Mut oligonucleotides (4 μM) recorded in the presence of 100 mM K+; B. Representative CD spectra of 4 μM RET 
oligonucleotides recorded in the presence of 100 mM K+ and 16 μM NDI; C. Image of a typical Taq polymerase stop assay. The RET FL Mut 
and RET I-IV Mut templates were amplified by the Taq polymerase in the absence (lanes 1) and in the presence of 10 mM K+, alone (lanes 2) 
or combined with 0.2 μM NDI (lanes 3). Lane M: Ladder of markers; P: unreacted labelled primer. The base sequence of the RET FL template 
corresponding to the stop sites is shown on the right of the gel image. G bases are shown in bold; D. Quantification of basal luciferase activity 
in MZ CRC-1 and TT cells following transfection with pGL3-RETAwt or pGL3-RETAmut vectors. Data have been reported as luciferase activity 
upon normalization to protein content and represent mean values ± s.d.. **P<0.01; ***P<0.001; E. Assessment of luciferase activity in pGL3-
RETAwt (black columns)- and pGL3-RETAmut (white columns)-transfected MTC cells exposed to the indicated amounts of NDI. Data have 
been reported as relative luciferase activity in treated vs. untreated cells and represent mean values ± s.d. *P<0.05; **P<0.01.
Table 1: Melting temperature (Tm) values of G4-folding oligonucleotides (4 μM), corresponding to G-rich regions of 
the RET promoter, in the presence of increasing concentrations of K+ and in the absence (-) or presence (+) of NDI 
(16 μM) 
Sequence Tm values (°C)
K+ 10 mM K+ 25 mM K+ 100 mM
- + - + - +
RET FL 57.7 ± 0.1 >95 82.0 ± 2.2 >95 >95 >95
RET I-IV 58.2 ± 0.1 >95 64.7 ± 0.2 >95 81.9 ± 2.0 >95
RET II-V 64.9 ± 1.3 >95 67.2 ± 0.6 >95 77.6 ± 1.8 >95
Data are reported as mean values ± standard error. P values <0.0001.
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RET promoter-driven luciferase activity is 
markedly inhibited by the NDI derivative
The evidence that the G4-forming region within 
the RET promoter is essential for basal promoter activity 
[15, 16] and that it can be effectively stabilized by the 
NDI (Figure 3), led us to hypothesize that the compound 
could turn-off the expression levels of RET in intact 
cells through a G4 stabilization-based mechanism. To 
verify such a hypothesis, a gene reporter assay was 
carried out in MTC cells transfected with a luciferase 
reporter plasmid bearing the wild-type form of the RET 
promoter (pGL3-RETAwt) or its mutated variant (pGL3-
RETAmut) bearing G>A and G>T point mutations (Figure 
3A). Such mutations have been shown to remarkably 
impair the G4 folding capability of the sequence (Figure 
4A–4C), without affecting the consensus sequences for 
the binding of Sp1/ Sp3 transcription factors (verified 
by Jaspar 5.0-alpha @ jaspar.genereg.net), which are 
necessary for RET basal promoter activity [25]. Results 
indicated that transfection of MTC cells with pGL3-
RETAmut resulted in a ~20-time increase in luciferase 
activity compared to cells transfected with the wild-
type vector (Figure 4D). This finding is in keeping 
with CD analysis and shows unambiguously that, under 
“physiological conditions”, the wild-type G4 forming 
motif within RET promoter spontaneously folds into a 
G4 structure, which in turn may negatively control the 
oncogene expression. Moreover, the exposure of cells 
transfected with pGL3-RETAwt vector to increasing 
concentrations of NDI resulted in a significant and dose-
dependent inhibition of luciferase activity (Figure 4E), 
which ranged from 71.8 ± 1.5 % to 22.3 ± 1.5 % in MZ 
CRC-1 cells and from 63.6 ± 5.4 % to 31.8 ± 2.6 % 
in TT cells, with respect to pGL3-RETAwt- transfected 
cells in the absence of NDI. Conversely, a negligible 
inhibition of luciferase activity (<12 %) was observed 
in pGL3-RETAmut vector-transfected MTC cells at all 
tested NDI concentrations with respect to untreated 
cells (Figure 4E).
Overall, these findings confirm our initial hypothesis 
and indicate that NDI-mediated down-regulation of RET 
in MTC cell lines occurs as a consequence of the G4 
stabilizing capabilities of the compound.
The NDI derivative affects the in vivo 
tumorigenic potential of MTC cells
In the final step of the study, the in vivo antitumor 
activity of the NDI derivative was evaluated in 
RET-dependent MTC models obtained following 
xenotransplantation of MZ CRC-1 and TT cells into 
immunocompromised mice [26]. Dosing regimen 
and treatment schedule were chosen on the basis of 
preliminary dose optimization studies carried out by 
taking into account of available information present in the 
literature for a compound belonging to the same chemical 
family [27].
Upon systemic administration, the compound was 
well tolerated without any appreciable sign of general 
toxicity and with a restrained effect (<15%) in terms 
of average body weight loss. Interestingly, a significant 
tumor growth delay was observed in animals that had 
received 12 mg/kg i.p. of NDI, compared to vehicle-
treated mice (Figure 5A and Supplementary Figure S4A), 
with a maximum tumor volume inhibition (TVI) of 50% 
at day 55 (mean TV 1,057 ± 166.6 and 520.4 ± 35 mm3 in 
control and treated groups, respectively; P<0.01) and of 
37% at day 58 (mean TV 662 ± 87 and 416 ± 52 mm3 in 
control and treated groups, respectively; P<0.05) in MZ 
CRC-1 and TT xenografts, respectively (Figure 5B and 
Supplementary Figure S4B). Moreover, the biochemical 
assessment of the in vivo drug-mediated effects showed a 
marked reduction of the basal and phosphorylated forms 
of RET protein and an increase in cleavage of caspase-3 
in tumors explanted from NDI-treated mice with respect 
to controls (Figure 5C), thus providing evidence of 
pharmacodynamic activity and further confirming the 
in vitro observations. Furthermore, a remarkable reduction 
in the immunohistochemical staining for the proliferation 
marker Ki67 paralleled by a pronounced increase in the 
positivity to TUNEL coloration was appreciable in MZ 
CRC-1 tissue sections from treated animals compared to 
controls (Figure 5D).
DISCUSSION
RET oncogene-expressing MTC has been reported 
to retain dependence on RET activity for the maintenance 
of the malignant phenotype (i.e., oncogene addiction 
[28]) and, consequently, RET receptor represents an 
ideal therapeutic target. Its selective abrogation has been 
indeed actively pursued and several types of molecular 
weapons have been developed to affect RET expression 
or activity for therapeutic purposes in thyroid cancer [4]. 
In this context, the development of TKIs has represented a 
major progress for the treatment of the metastatic disease 
[5], though the lack of complete clinical responses and 
the onset of drug resistance highlight the dire need of 
ameliorating the therapeutic interventions for the advanced 
disease [4, 5].
In the present study, we showed that the exposure 
of RET oncogene mutant-expressing MTC cell lines to 
an NDI-based G4 ligand resulted in pronounced down-
regulation of RET expression at mRNA and protein level, 
as a consequence of the capability of the NDI derivative to 
stabilize the G4 structure that spontaneously forms within 
RET promoter [15, 16]. Our results support previous 
observation showing that the RET G4 structure is actually 
amenable of ligand-mediated stabilization. Specifically, 
it has been reported that in the presence of monovalent 
cations the G4-stabilizing agents telomestatin –a 
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macrocyclic natural product isolated from Streptomyces 
anulatus and formerly tested for its capability to stabilize 
G4 structures at telomeric level - was able to efficiently 
stabilize the G4 structure in a synthetic oligonucleotide 
carrying the RET promoter sequence [15]. In addition, 
it has been recently reported that NSC194598 (an 
indeno[1,2,3-de]quinazoline derivative) and berberine (a 
natural alkaloid containing a planar isoquinoline aromatic 
ring) interfered with the oncogene expression and impaired 
the growth of TT cells cultured in vitro by favouring the 
stabilization of RET G4 and likely preventing the correct 
assembly of the transcription complex at gene promoter 
level [29, 30].
In our experimental conditions, the NDI-mediated 
decrease in RET levels was tightly associated with a 
marked impairment of MTC cell growth, which in turn 
was rescued, though partially, by the ectopic expression 
of RET protein. Such a partial rescue in the phenotype 
may reside in the multiple targeting properties of the 
NDI derivative. In fact, the ligand showed to markedly 
inhibit the growth of melanoma cells through its capability 
to efficiently interact with telomeric G4s [17] and it 
displayed fairly good binding properties for G4 structures 
forming within the promoter regions of MYC and KIT 
(Supplementary Table S2, [31]) as well as of BCL2 [31], 
other than RET. Nonetheless, its capability to inhibit the 
expression levels of each oncogene in living cells was not 
observed straightforwardly, being rather dependent on the 
cell context [31]. In fact, data reported in the present study 
show that the same molecule markedly impaired RET 
expression levels in MTC cell lines with a negligible or 
even contrasting effect on BCL2 and MYC protein amounts 
(Figure 2B). However, we cannot currently rule out that 
the phenotype observed in NDI-treated MTC cells may be 
the result of ligand-mediated multiple action on additional 
G4 targets (e.g., KIT and telomeres [17, 31]), other than 
RET, that may be relevant for the disease [32, 33]. In this 
regard, it should be taken into account that i) cell factors 
(e.g., specific G4 interacting proteins) or cell conditions 
(e.g., chromatin status or transcriptional activity) may 
impinge on the ligand/G4 interaction, even in a cell-type 
dependent manner; ii) G4 structures with similar topologies 
Figure 5: The NDI derivative inhibits MTC tumor growth in vivo. A. Growth curves of MZ CRC-1 tumors in vehicle-treated 
mice (●) and upon i.p. administration of 12 mg/kg NDI derivative (○). Data have been reported as average tumor volume (mm3) ± S.E.M.; 
*P<0.05, **P<0.01; B. Tumor volume distribution in vehicle- and NDI-treated animals at day 55, at which the maximum TVI% was 
observed; C. Representative western immunoblotting showing basal and phosphorylated (pRET/Y1062) RET as well as cleaved caspase-3 
protein amounts in MZ CRC-1 representative tumors grown in vivo and collected at day 55; D. Representative images showing the 
immunohistochemical staining for Ki67 (cell proliferation marker) and TUNEL (apoptosis marker) in MZ CRC-1 tumor tissues from 
control and treated mice, collected at day 55. Scale bar: 30 μm; magnification ×40.
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can be amenable of stabilization by the same ligand and 
that iii) the vast majority of ligands reported thus far to 
interact with promoter G4s were primarily conceived as 
telomeric G4 ligands (e.g., telomestatin and RHPS4) [13, 
15]. Nonetheless, pieces of evidence indicate that the 
“promiscuous” nature (i.e., the capability to interacts with 
multiple G4 targets) of some G4 ligands [11, 13, 31, 34, 
35] may be of therapeutic value, as it has been recently 
shown for an NDI derivative able to simultaneously target 
the G4 within BCL2 and KRAS gene promoters in an in 
vivo model of pancreatic cancer [35].
A remarkable apoptotic response was observed 
in NDI-treated MZ CRC-1 cells, whereas no apoptosis 
induction was detected in TT cells following the exposure 
to an equitoxic amount of the compound. By contrast, 
NDI-treated TT cells were characterized by a durable cell 
growth arrest, which was associated with increased levels 
of markers usually connected to cell senescence, such as 
the accumulation over time of the cyclin-dependent kinase 
inhibitor p21waf1 and of γ-H2AX. Such a different response 
of MTC cells to NDI treatment may be accounted by the 
evidence that TT cells are basically more refractory than 
MZ CRC-1 cells to different types of apoptotic stimuli 
[22, 23]. In keeping with this is our observation that MCF-
7 cells, which are resistant to apoptosis induction due to 
the lack of caspase-3 [24], behaved similarly to TT cells 
upon the exposure to NDI. By analogy, we previously 
showed that the same derivative contributed to a senescent 
phenotype by inducing a prolonged cell growth arrest and 
a time-dependent increase in the expression levels of 
p21waf1 in an in vitro model of human melanoma cells [17].
Finally, and most importantly, we here reported 
that, upon systemic administration, the NDI derivative 
retained its capability to interfere with RET expression, to 
remarkably inhibit tumor growth and to induce apoptosis 
in MTC tumors grown in vivo without apparent sign of 
general toxicity. This evidence contributes to underscore 
the therapeutic potential of in vivo G4 stabilization-based 
approaches as well as to furnish indication on the safety 
profile of G4 interacting molecules.
Overall, our data support the notion that small 
molecule-mediated RET G4 stabilization may represent 
a valid molecular approach for the therapeutic regulation 
of RET signaling in MTC and contribute to furnish the 
biological rationale for future development of novel G4 
stabilizing-based treatment options for MTC or other 
neoplastic diseases, such as breast cancers [36] and 
neuroblastoma [37] for which RET may represent a 
suitable therapeutic target.
MATERIALS AND METHODS
Cell lines and reagents
The human TT cell line, derived from the primary 
tumor of a sporadic MTC, was purchased from the 
American Type Culture Collection (LGC Standards 
S.r.l., Sesto S. Giovanni, Italy). The MZ CRC-1 cell 
line, derived from the malignant pleural effusion of 
a patient with a metastatic MTC, was kindly provided 
by Dr. Robert Hofstra, University of Groningen, The 
Nederlands [22]. The MCF-7 breast cancer cells were 
purchased from LGC Standards S.r.l. The cell lines 
were tested for the absence of Mycoplasma fortnightly, 
monitored periodically for DNA profile of short tandem 
repeats by the AmpFISTR Identifiler PCR amplification 
kit (PN4322288, Applied Biosystems/Life Technologies 
Italia, Monza, Italy). MTC cells were also periodically 
tested for expression/constitutive activation of RET 
by western blotting. Cells were maintained in the 
logarithmic growth phase in 5% CO2 at 37°C using 
appropriate culture media supplemented with 10% fetal 
bovine serum.
The NDI derivative was prepared according to our 
previously reported synthetic protocol [17] and purified 
by preparative HPLC, using a C-18 reverse phase column 
(OBD-Sun Fire Prep C-18 5μm, 100 x 30 mm, waters 
eluent CH3CN : H2O 0.1% TFA), with ≥ 99.9% purity 
(evaluated by two different HPLC protocols, using a 
XSelect HSS C18 2.5 μm, 50 x 4.6 mm, waters column; 
see Supplementary Figure S5 and S6 for details). Addition 
of 1 ml HCl 1 M solution to 20 ml of the resulting eluate 
from preparative HPLC, followed by solvent evaporation 
under vacuum and lyophilisation, afforded the final NDI 
as hydrochloride (NDIx3HCl, Figure 1A) red powder. 
The compound was dissolved in DMSO (Sigma-Aldrich 
S.r.l., Milano, Italy) and stored as stock solution at 
-20°C. Working solutions of the NDI at the appropriate 
concentration were prepared in cell culture media just 
before use.
Mouse monoclonal antibodies anti-p53 (Abcam, 
Cambridge, UK), anti-p21waf1 (NeoMarkers, Fremont, CA, 
USA) and anti-Ki67 (MIB-1, Dako Italia S.p.A, Cernusco 
S/N, Italy) along with rabbit polyclonal antibodies anti-
Ret (H-300), anti-phospho-Ret/Y1062 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), anti-caspase-9, 
anti-cleaved caspase-3/Asp175 and anti-c-Myc (Cell 
Signaling Technology, Danvers, MA, USA), anti-p27Kip1, 
anti-Bcl-2, anti-H2AX, anti-γ-H2AX and anti-β-actin 
(Abcam.) were used in the study.
Oligonucleotides used for the biophysical analysis 
are reported in Table S1 and were purchased from 
Sigma-Aldrich S.r.l.. T4 polynucleotide kinase was from 
Fermentas (Milan, Italy), [γ-32P]ATP was from Perkin 
Elmer (MA, USA).
In vitro studies
For the assessment of NDI-mediated effect on cell 
growth, cells were seeded at the appropriate density in 
6-well plates and exposed to increasing concentrations 
(0.005, 0.05, 0.5, 5 and 50 μM) of freshly dissolved 
Oncotarget49660www.impactjournals.com/oncotarget
compound. After a 48-h exposure to the NDI, cells were 
collected and counted in a particle counter (Coulter 
Counter, Coulter Electronics, Luton, UK). The IC50 
and IC80 (drug concentration inhibiting cell growth 
by 50 % and 80 %, respectively) values for each cell 
line were calculated from dose-response curves. In the 
medium-term cell growth assay, cells were seeded at 
the appropriate density in 6-well plates, exposed to a 
concentration of NDI corresponding to the IC50 for 24, 
48, 72 and 96 h. Adherent cells were then collected and 
counted as described above.
Apoptosis was assessed by the terminal 
deoxynucleotidyl transferase dUTP nick-end labelling 
(TUNEL) assay using the In situ Cell Death Detection Kit, 
POD (Roche Diagnostic, Monza, Italy). Briefly, NDI-treated 
cells were harvested at the indicated time points and fixed 
in 4% paraformaldehyde for 45 min at room temperature. 
After rinsing with phosphate buffered saline (PBS), the cells 
were permeabilised in a solution of 0.1 % Triton X-100 in 
0.1 % sodium citrate for 2 min in ice. Samples washed 
with PBS were then incubated in the TUNEL reaction 
mixture (Boehringer Mannheim, Mannheim, Germany) 
for 1 h at 37 °C in the dark, and after rinsing with PBS 
they were suspended in PBS and analyzed by a FACScan 
cytofluorimeter (BD Biosciences, Milano, Italy). The results 
were expressed as the percentage of TUNEL-positive cells 
in the overall cell population.
Details on the procedure used for the ectopic over-
expression of wild-type or mutant RET [38] may be found 
in the Supplementary Information.
Real-time RT-PCR
Total RNA was isolated from untreated and NDI-
treated cells using Qiagen RNeasy Mini Kit (Qiagen S.r.l., 
Milano, Italy) and DNase I-digested. The expression 
levels of RET mRNA were assessed by real-time RT-
PCR by TaqMan® Assay (Hs01120030_m1; Applied 
Biosystems/Life Technologies Italia). Amplifications 
were run on the 7900HT Fast Real-Time PCR System 
(Applied Biosystems/Life Technologies Italia). Data were 
analyzed by SDS 2.2.2 software (Applied Biosystems/Life 
Technologies Italia) and reported as relative quantity with 
respect to a calibrator sample (untreated cells) using the 
2-ΔΔCt method [39], where Ct represents the threshold 
cycle. RNase P (PN4316844) was used as normaliser.
Data obtained in the time-course assessment of RET 
mRNA levels have been reported according to the 2-ΔC’T 
method, where ΔC’T = CT, time x - CT, time 0.(i.e., 48 h after drug 
exposure) [39].
Western immunoblotting
Protein levels were assessed by western blot 
analyses of whole cell lysates prepared according to 
standard procedures. Proteins (40 μg) were fractioned by 
SDS-PAGE and transferred onto Hybond nitrocellulose 
filters (GE Healthcare Italia, Milano, Italy). Filters were 
blocked in PBS-Tween 20/5 % skim milk and incubated 
overnight with primary antibodies (see above). The filters 
were then probed with secondary peroxidase-linked whole 
antibodies (GE Healthcare Italia) and bound antibodies 
visualized by SuperSignal® West PICO chemiluminescent 
detection system (Fisher Scientific, Pittsburgh, PA, USA). 
Filters were then subjected to autoradiography. An anti-β-
actin (ACTB) antibody was used on each blot to confirm 
equal protein loading.
Spectroscopic analyses
Oligonucleotides (Supplementary Table S1) were 
diluted from stock to a final concentration of 4 μM in 
lithium cacodylate buffer (10 mM, pH 7.4) and, where 
appropriate, KCl at different concentration (10-25-100 
mM). All samples were annealed by heating at 95 °C for 5 
min, gradually cooled to room temperature and measured 
after 24 h. The compound was added after DNA annealing 
at the final concentration of 16 μM or 4 μM. CD spectra 
were recorded on a Chirascan-Plus (Applied Photophysics, 
Leatherhead, UK) equipped with a Peltier temperature 
controller using a quartz cell of 5-mm optical path length 
and scanning a speed of 50 nm/min with a response time of 
4 sec over a wavelength range of 230-320 nm. The reported 
spectrum of each sample represents the average of 2 scans 
at 20 °C and it is baseline corrected for signal contributions 
due to the buffer. Observed ellipticities were converted to 
mean residue ellipticity (θ) = deg×cm2×dmol−1 (mol. ellip.). 
For the determination of Tm, spectra were recorded over a 
temperature range of 20-95 °C, with temperature increase 
of 5 °C/min. Tm values were calculated according to the 
van’t Hoff equation, applied for a two state transition from 
a folded to unfolded state, assuming that the heat capacity 
of the folded and unfolded states are equal [40].
Taq polymerase stop assay
RET Taq primer (Table S1) was 5′-end labeled with 
[γ-32P]ATP using T4 polynucleotide kinase at 37 °C for 
30 min. The labeled primer (final concentration 72 nM) 
was annealed to the template (final concentration 36 
nM) in lithium cacodylate buffer (10 mM, pH 7.4) in the 
presence or absence of KCl 10 mM. Primer extension was 
conducted with 2U of AmpliTaq Gold DNA polymerase 
(2U/reaction, Applied Biosystem/Life Technologies 
Italia) at 60 °C for 30 min. Where specified, samples were 
incubated with increasing concentration of NDI derivative 
(0.008, 0.04, 0.2 and 1μM) in the presence of 10 mM 
KCl, and primer extension was performed as described 
above. Reactions were stopped by ethanol precipitation 
and primer extension products were separated on a 15 % 
denaturing gel, and visualized by phosphorimaging 
(Typhoon FLA 9000, GE Healthcare Italia).
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Luciferase assay
The reporter plasmid pGL3-RETAwt [41] containing 
a 162-bp fragment spanning from -108 to +53 relative to 
the TSS of RET promoter, placed upstream of the Firefly 
Luciferase reporter gene, was kindly provided by Dr I. 
Ceccherini (Istituto Giannina Gaslini, Genua, Italy). The 
mutant derivative of pGL3-RETAwt vector carrying a mutated 
sequence of RET promoter was generated by polymerase 
chain reaction (PCR)-based site directed mutagenesis, 
according to standard procedure. The RET mutated 
sequences were obtained by inserting two point mutations 
(G>A and G>T) within the forward primer sequence. Briefly, 
the PCR reaction was carried out using pGL3-RETAwt vector 
as template and forward and reverse primers (Supplementary 
Table S1) bearing, respectively, unique Kpn I and Hind III 
restriction sites at the 5′ end. The PCR-amplified fragment 
and pGL3-RETAwt vector were then digested with Kpn I and 
Hind III restriction enzymes (New England BioLabs Inc., 
Ipswich, MA) and purified by agarose gel electrophoresis. 
The gel-purified RETAmut fragment was then inserted into the 
KpnI/HindIII digested vector to generate the pGL3-RETAmut 
plasmid. For the assessment of luciferase activity MZ CRC-1 
and TT cells were seeded at the appropriate density (0.6×105 
cells/well) in culture plates. Seventy-two h after seeding, 
cells were transfected with 0.5 μg/well of pGL3-RETAwt 
or of pGL3-RETAmut using Lipofectamine3000TM (Life 
Technologies) in standard growth medium containing 10 % 
FBS, according to the manufacturer’s protocol. After 48 h, 
cells were treated for 24 h with increasing concentrations 
(0.5-2.5 μM) of NDI. Luciferase activity was measured in cell 
lysates using the Luciferase Assay System (Promega Italia, 
Milano, Italy), according the manufacturer’s instructions, and 
normalized to total protein content.
In vivo studies
The in vivo antitumor activity of the NDI derivative 
was assessed using 8-10-week old female SCID mice 
(Charles River, Calco, Italy) xenotransplanted with MZ 
CRC-1 or TT cells. Experiments were approved by the Ethics 
Committee for Animal Experimentation of the Fondazione 
IRCCS Istituto Nazionale Tumori of Milan according to 
institutional guidelines, in compliance with national and 
international laws and policies. Mice were maintained in 
laminar flow rooms under constant temperature and humidity 
and with free access to food and water. Briefly, exponentially 
growing MZ CRC-1 (2×107) and TT (3×107) cells were 
subcutaneously injected into the right flank of mice. Before 
starting the treatments, animals were randomly assigned to 
control or treated groups (n=8/group). The NDI derivative 
was dissolved in PBS at the proper final concentration just 
before treatment and administered intraperitoneally (i.p.) at 
12 mg/kg every two days for twelve times (q2d×12). The 
compound was administered to animals when tumors reached 
a volume of approximately 100 mm3 after cell injection. 
Tumor growth in control and treated groups was followed by 
biweekly measurements of tumor diameters with a Vernier 
caliper. Tumor volume (TV) was calculated according to the 
formula: TV (mm3) = d2×D/2 where d and D are the shortest 
and the longest diameter, respectively. Treatment efficacy 
was assessed as tumor volume inhibition percentage (TVI 
%) in treated vs. control mice, calculated as 100-(mean TV in 
treated animals/mean TV in controls × 100). The toxicity was 
evaluated as body weight loss (BWL).
Vehicle- and NDI-treated tumors were explanted 
at the end of treatments for subsequent analyses. 
Immunohistochemistry (IHC) was carried out at the 
institutional IHC facility on formalin-fixed, paraffin 
embedded (FFPE) tissue sections (4 μm thick). Briefly, 
immunohistochemical staining for the proliferation 
marker was performed using an anti-Ki67 antibody, 
whereas apoptosis was assessed by the In situ Cell Death 
Detection Kit, POD (Roche Diagnostic), according to 
the manufacturer’s protocol. Immunoreactions were 
developed using the streptavidin-biotin-peroxidase 
technique, followed by counterstaining with haema-
toxylin (Ki67 staining) or by anti-fluorescein antibody 
Fab fragments (TUNEL assay) conjugated with horse-
radish peroxidase (POD). Images were acquired 
(magnification ×40) using a Nikon Eclipse E600 
microscope (Nikon, Japan) by the ACT-1 software 
(Nikon) and processed by Adobe Photoshop Image 
Reader 7.0.
Statistical analysis
Data are reported as mean values ± s.d. (if not 
otherwise indicated) from at least three independent 
experiments. Two-sided Student's t test was used for 
the statistical evaluation of data. P values <0.05 were 
considered statistically significant.
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